Comparative efficacy and safety of oral Chinese patent medicines combined with conventional therapy for coronary heart disease complicated by diabetes: a systematic review and network meta-analysis - Report - MDSpire
Advertisement
Comparative efficacy and safety of oral Chinese patent medicines combined with conventional therapy for coronary heart disease complicated by diabetes: a systematic review and network meta-analysis
Efficacy and Safety Comparison of Oral Chinese Patent Medicines for CHD
Overview
This systematic review and network meta-analysis evaluated the efficacy and safety of oral Chinese patent medicines (OCPMs) combined with standard treatment for coronary heart disease (CHD) in patients with diabetes. The findings suggest that OCPMs provide multidimensional benefits, including improvements in glycemic control and cardiovascular outcomes.
Background
Coronary heart disease (CHD) is a leading cause of morbidity and mortality, particularly in patients with diabetes mellitus (DM), which complicates management and worsens prognosis. The integration of traditional Chinese medicine, specifically oral Chinese patent medicines (OCPMs), into standard treatment regimens may offer additional therapeutic benefits. Understanding the comparative efficacy and safety of these adjunctive therapies is crucial for optimizing patient outcomes.
OCPMs combined with conventional therapy provide significant improvements in various cardiovascular and metabolic parameters.
Shexiang Baoxin Pills showed optimal efficacy in reducing triglycerides and improving HDL cholesterol.
Tongxinluo Capsules were most effective in lowering postprandial blood glucose levels.
Guanxinning Tablets demonstrated significant reductions in glycated hemoglobin.
Liuwei Dihuang Pills were associated with a lower incidence of major adverse cardiovascular events.
Overall, OCPMs can enhance treatment outcomes for patients with CHD and diabetes.
Clinical Implications
The integration of OCPMs into standard treatment regimens for patients with CHD and diabetes may enhance glycemic control and cardiovascular health. Clinicians should consider these adjunctive therapies while being mindful of the variability in study quality and the need for further high-quality research.
Conclusion
OCPMs offer promising benefits for managing CHD in diabetic patients, but further rigorous studies are necessary to validate these findings and ensure safe clinical application.
